Sujal Shah, Interim President & CEO at CymaBay Therapeutics, Inc. (CBAY), bought 18,033 shares at $7.35 ($132K) on 2017-07-20, disclosed to the SEC on 2017-07-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.29 | 891 | $6K | 4.9% |
| 2 | $7.30 | 400 | $3K | 2.2% |
| 3 | $7.31 | 576 | $4K | 3.2% |
| 4 | $7.32 | 100 | $732 | 0.6% |
| 5 | $7.35 | 8,033 | $59K | 44.6% |
| 6 | $7.35 | 8,033 |
| $59K |
| 44.6% |
| Total | $7.34 avg | 18,033 | $132K | 100% |
| Filing → |
| CBAY | SELL | 2023-10-10 | $1.8M | — | Filing → |
| CBAY | BUY | 2022-06-07 | $200K | — | Filing → |
| CBAY | BUY | 2019-10-15 | $22K | — | Filing → |